A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases
Authors:
- Salvatore CaponnettoSCSalvatore Caponnetto
- Ornella CantaleOCOrnella Cantale
- Alex FriedlaenderAFAlex Friedlaender
- Fabio GomesFGFabio Gomes
- Sunil DaryananiSDSunil Daryanani
- Alain GelibterAGAlain Gelibter
- Alessio CortelliniACAlessio Cortellini
- Dario GiuffridaDGDario Giuffrida
- Alfredo AddeoAAAlfredo Addeo
- Giuseppe Luigi BannaGiuseppe Luigi Banna
Open Access
- 12 January 2021
- journal article
- review article
- Published by MDPI AG in Journal of Molecular Pathology
- Vol. 2 (1) , 1-10
Abstract
Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of the efficacy of different-generation EGFR-tyrosine kinase inhibitors (TKI) on BMs from NSCLC are currently limited. We identified studies comparing different EGFR-TKIs for NSCLC through Pubmed literature search and selected those with neurological outcome data. By two retrospective analyses, Erlotinib showed longer neurological time-to-progression (30 months vs. 15.8 months, P = 0.024) and reduced the risk of central nervous system (CNS) progression (Hazard Ratio (HR) 0.25; 95% CI, 0.08–0.81; P = 0.021) compared to Gefitinib. In a phase 2b randomized trial, 16% of patients with BMs had a similar Progression Free Survival (PFS) (HR 0.76, 95% CI 0.41–1.44) or Overall Survival (OS) (HR 1.16, 95% CI 0.61–2.21) with Afatinib versus Gefitinib; a lower risk of developing subsequent BMs with Afatinib than Gefitinib (HR 0.49; 95% CI 0.34–0.71; P < 0.001) was reported by a retrospective study. A randomized phase 3 trial proved that patients with BMs treated with Osimertinib had longer PFS (HR 0.47, 95% CI 0.30–0.74) and OS (HR 0.79, 95% CI 0.61–1.01) than with Gefitinib, and lower incidence of CNS progression (6% vs. 15%, respectively). Although there is limited evidence, differences in CNS activity may exist between EGFR-TKIs.Keywords
This publication has 40 references indexed in Scilit:
- Systemic treatment of brain metastases in non-small cell lung cancerEuropean Journal of Cancer, 2020
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancerBritish Journal of Cancer, 2019
- The crucial role of predicting brain metastases development in non-small cell lung cancer patientsJournal of Thoracic Disease, 2018
- Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal DiseaseTargeted Oncology, 2018
- Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancerJournal of Thoracic Disease, 2017
- The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancerOncoTargets and Therapy, 2017
- Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER studyPLOS ONE, 2015
- Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central EuropeJournal of Thoracic Oncology, 2015
- Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung CancerJournal of Thoracic Oncology, 2015
- A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesOncotarget, 2015